JP2024063016A5 - - Google Patents
Info
- Publication number
- JP2024063016A5 JP2024063016A5 JP2024017576A JP2024017576A JP2024063016A5 JP 2024063016 A5 JP2024063016 A5 JP 2024063016A5 JP 2024017576 A JP2024017576 A JP 2024017576A JP 2024017576 A JP2024017576 A JP 2024017576A JP 2024063016 A5 JP2024063016 A5 JP 2024063016A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- antagonist
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1802487.7 | 2018-02-15 | ||
| GBGB1802487.7A GB201802487D0 (en) | 2018-02-15 | 2018-02-15 | Cytokine combination therapy |
| JP2020543512A JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
| PCT/EP2019/053890 WO2019158728A1 (en) | 2018-02-15 | 2019-02-15 | Combined antagonists against il-5/il-5r and either il-4/il-4r or il-13/il-13r |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Division JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024063016A JP2024063016A (ja) | 2024-05-10 |
| JP2024063016A5 true JP2024063016A5 (cg-RX-API-DMAC7.html) | 2026-04-14 |
Family
ID=61783635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Active JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
| JP2024017576A Pending JP2024063016A (ja) | 2018-02-15 | 2024-02-08 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543512A Active JP7808430B2 (ja) | 2018-02-15 | 2019-02-15 | Ｉｌ－５／ｉｌ－５ｒ、及び、ｉｌ－４／ｉｌ－４ｒ又はｉｌ－１３／ｉｌ－１３ｒに対する組合せアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12030949B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3752529A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7808430B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112041342B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019221627B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3088734A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201802487D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276344A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019158728A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| CN111825766B (zh) * | 2019-10-31 | 2021-05-11 | 上海洛启生物医药技术有限公司 | 抗il-4r单域抗体及其应用 |
| WO2021249555A1 (en) * | 2020-06-12 | 2021-12-16 | Beijing Vdjbio Co., Ltd. | Fusion polypeptide |
| KR102773428B1 (ko) | 2020-08-05 | 2025-02-28 | 신테카인, 인크. | Il10 수용체 결합 분자 및 사용 방법 |
| EP4192489A4 (en) | 2020-08-05 | 2024-12-11 | Synthekine, Inc. | IL2RB-BINDING MOLECULES AND METHODS OF USE |
| US12540188B2 (en) | 2020-08-05 | 2026-02-03 | Synthekine, Inc. | IL10Rα/IL2Rγ synthetic cytokines |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| CN117903303A (zh) * | 2020-08-20 | 2024-04-19 | 南京融捷康生物科技有限公司 | Il-5的结合分子及其应用 |
| KR102697769B1 (ko) * | 2020-09-14 | 2024-08-23 | 아주대학교산학협력단 | 인터루킨-4 수용체 알파 서브유닛과 인터루킨-5 수용체 알파 서브유닛에 동시에 결합하는 이중특이항체 및 이의 용도 |
| CN113307870B (zh) * | 2020-10-30 | 2022-12-23 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
| CN114605539B (zh) * | 2020-12-09 | 2024-01-02 | 南京融捷康生物科技有限公司 | 人源化的抗IL-4Rα单域抗体及其应用 |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| CN114805572B (zh) * | 2021-01-22 | 2022-12-13 | 上海济煜医药科技有限公司 | 抗原结合蛋白及其应用 |
| AU2023274641A1 (en) * | 2022-05-23 | 2024-09-19 | Regenecore Biotech Co., Ltd | Stable antibody preparation |
| CN116606375B (zh) * | 2023-07-03 | 2025-10-03 | 珠海瑞思普利医药科技有限公司 | 抗人白介素5纳米抗体及其应用 |
| WO2026020024A1 (en) * | 2024-07-19 | 2026-01-22 | Bambusa Therapeutics, Inc. | Multispecific binding agents and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| WO2009121847A2 (en) | 2008-04-02 | 2009-10-08 | Apogenix Gmbh | Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| EP2417164A1 (en) | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-2/anti-c-met antibodies |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| MX340696B (es) * | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anticuerpos anti-c5a y metodos para usar los anticuerpos. |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| BR112013023918A2 (pt) | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
| GB2504139B (en) | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| EP3517548A1 (en) | 2012-03-13 | 2019-07-31 | NovImmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2013259276B2 (en) | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| JP6385357B2 (ja) | 2012-11-27 | 2018-09-05 | アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ | 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途 |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| US10047163B2 (en) | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CN111437387B (zh) * | 2013-06-21 | 2024-10-01 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗鼻息肉症的方法 |
| WO2015033223A2 (en) | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN115160441A (zh) | 2013-09-26 | 2022-10-11 | 埃博灵克斯股份有限公司 | 双特异性纳米抗体 |
| BR112016006929A2 (pt) | 2013-10-11 | 2017-09-19 | Hoffmann La Roche | Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| RU2609627C2 (ru) | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| US20160272706A1 (en) * | 2015-01-12 | 2016-09-22 | Medimmune Limited | Il-13 binding proteins and uses thereof |
| MA41375A (fr) | 2015-01-22 | 2017-11-28 | Lilly Co Eli | Anticorps igg bispécifiques et leurs procédés de préparation |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| GB201707484D0 (en) | 2017-05-10 | 2017-06-21 | Argenx Bvba | Method of preparing ph-dependent antibodies |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
-
2018
- 2018-02-15 GB GBGB1802487.7A patent/GB201802487D0/en not_active Ceased
-
2019
- 2019-02-15 JP JP2020543512A patent/JP7808430B2/ja active Active
- 2019-02-15 CN CN201980025923.3A patent/CN112041342B/zh active Active
- 2019-02-15 AU AU2019221627A patent/AU2019221627B2/en active Active
- 2019-02-15 CA CA3088734A patent/CA3088734A1/en active Pending
- 2019-02-15 US US16/966,237 patent/US12030949B2/en active Active
- 2019-02-15 WO PCT/EP2019/053890 patent/WO2019158728A1/en not_active Ceased
- 2019-02-15 EP EP19715814.0A patent/EP3752529A1/en active Pending
-
2020
- 2020-07-28 IL IL276344A patent/IL276344A/en unknown
-
2024
- 2024-02-08 JP JP2024017576A patent/JP2024063016A/ja active Pending
- 2024-06-28 US US18/758,267 patent/US20240352138A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024063016A5 (cg-RX-API-DMAC7.html) | ||
| JP2021513974A5 (cg-RX-API-DMAC7.html) | ||
| AU2022241522B2 (en) | Bispecific antibody to a-syn/igf1r and use thereof | |
| AU2023203440A1 (en) | Antibodies that specifically bind to TL1A | |
| JP2023113686A (ja) | ｐＨ依存的抗体の調製方法 | |
| JP2022110117A (ja) | α－シヌクレインに対する抗体およびその使用 | |
| JP2010538608A5 (cg-RX-API-DMAC7.html) | ||
| WO2009052081A4 (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
| BR112013016235B1 (pt) | Anticorpo isolado, uso de um anticorpo, ácido nucleico, célula transformada e composição farmacêutica | |
| JP2018509153A (ja) | Ｔｓｌｐ結合タンパク質 | |
| JP6898251B2 (ja) | 組換え抗体分子の単量体化方法 | |
| CA2727992A1 (en) | Stable and soluble antibodies inhibiting tnf.alpha. | |
| JP2019527194A5 (cg-RX-API-DMAC7.html) | ||
| AU2023202595B2 (en) | BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF | |
| WO2024120479A1 (zh) | 一种针对IgE的抗体或其抗原结合片段以及Fc变体 | |
| CA3192208A1 (en) | Anti-par-2 antibodies and methods of use thereof | |
| CA3096791A1 (en) | Cell engaging binding molecules | |
| TW202525846A (zh) | 抗ｉｌ—１３多特異性抗體構築體及其用途 | |
| KR20250042149A (ko) | Ige-fceri의 디스플레이서 | |
| JPWO2021162098A5 (cg-RX-API-DMAC7.html) | ||
| US20260028396A1 (en) | Anti-myostatin antibodies and methods | |
| US11981727B2 (en) | Monospecific and bispecific antibodies and antigen binding fragments thereof | |
| US20240117056A1 (en) | Epidermal growth factor receptor variant iii antibodies | |
| US20260109769A1 (en) | Pd-1 bnding proteins, vegf and pd-1 bispecific binding proteins, compositions, and methods of use | |
| WO2026064551A2 (en) | Methods of use for interleukin-4 receptor alpha antibodies |